SIGN UP FOR UPDATES!
Sign up for Englemed updates from TwitterSign up for Englemed updates from Facebook
ENGLEMED
Contact Englemed
Our contact email address.
We can provide a specialist, tailored health and medical news service for your site.
Click here for more information
RSS graphic XML Graphic Add to Google
About Englemed news services - services and policies.
Englemed News Blog - Ten years and counting.
Diary of a reluctant allergy sufferer - How the British National Health Service deals with allergy.
BOOKS AND GIFTS THIS WAY!
BookshopFor books on women's health, healthy eating ideas, mental health issues, diabetes, etc click here
SEARCH THIS SITE
Copyright Notice. All reports, text and layout copyright Englemed Ltd, 52 Perry Avenue, Birmingham UK B42 2NE. Co Registered in England No 7053778 Some photos copyright Englemed Ltd, others may be used with permission of copyright owners.
Disclaimer: Englemed is a news service and does not provide health advice. Advice should be taken from a medical professional or appropriate health professional about any course of treatment or therapy.
FreeDigitalPhotos
www.freedigitalphotos.net
FreeWebPhotos
www.freewebphoto.com
FROM OUR NEWS FEEDS
Macrophage link to hypertension
Thurs Jan 17th - Macrophages in the immune system may have a key role in hypertension, according to a project in Edinburgh, UK. More
Haemochromatosis gene’s impact on carriers
Thurs Jan 17th - A genetic variant that causes haemochromatosis is more dangerous than previously thought, according to a new UK analysis. More
RECENT COMMENTS
On 08/02/2018 David Kelly wrote:
Would you like to write a piece about this to be i... on Researchers unveil new pain re...
On 23/10/2017 Cristina Pereira wrote:
https://epidemicj17.imascientist.org.uk/2017/06/21... on HIV breakthrough - MRC...
On 12/09/2017 Aparna srikantam wrote:
Brilliant finding! indeed a break through in under... on Leprosy research breakthrough...
On 01/07/2017 Annetta wrote:
I have been diagnosed with COPD for over 12 years.... on Seaweed plan for antimicrobial...
On 12/03/2017 Steph wrote:
The photo you have paired with this article is its... on 'Fat shaming' limits...
OTHER NEWS FEEDS OF INTEREST
HEALTHY EATING BOOKS
ENGLEMED HEALTH NEWS

Statin adherence and dose important for high risk patients

Monday December 10th, 2018

Patients at high risk from cardiovascular disease should be prescribed high doses of statins and adherence monitored closely, according to a new observational analysis.

According to the study of UK GP records, 12,000 cardiovascular events a year could be prevented by stepping up prescribing of statins.

Researchers at Imperial College, London, and Leicester University studied patients with established cardiovascular disease - together with those with diabetes and those with chronic kidney disease.

They identified some 30,000 patients who had recently started statin treatment from the Clinical Practice Research Datalink, which includes 450 practices.

They found that patients with high adherence and high dose prescriptions enjoyed a 40% reduction in their risk of cardiovascular events.

This compared with a 5% reduction for those on low dose statins and poor adherence, according to the report in JAMA Network Open.

Researcher Professor Kausik Ray, from Imperial College, said: “In terms of risk reduction, we can see the people who do the best are those who are adhering to the recommended dosage and are on more potent drug regimens.

“But if someone is not going to take a treatment as recommended, they may actually be better off on higher doses of statins so that when they are taking the medication, they are achieving greater cholesterol reductions.”

Fellow researcher Professor Kamlesh Khunti said: “Adherence to lipid lowering therapy is poor within first six months, with studies showing that 40–60% of people are not adherent to statin therapies.

“This novel concept of a measure of adherence and intensity is likely to be applicable to other medications such as antihypertensive and glucose lowering therapies as well.”

Association of a Combined Measure of Adherence and Treatment Intensity with Cardiovascular Outcomes in Patients with Atherosclerosis or Other Cardiovascular Risk Factors Treated with Statins and/or Ezetimibe. JAMA Network Open 7 December 2018; doi: 10.1001/jamanetworkopen.2018.5554

Tags: Heart Health | Pharmaceuticals | UK News

Printer friendly page Printer friendly page

Comment on this article:

Name:
Email:
Comment:
<a>,<b> & <p> tags allowed
Please enter the letters displayed:
(not case sensitive)
CATEGORIES